Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-04-07

Clinical Trial Update: Pegvisomant And Sandostatin LAR Combination Study [Phase 4]

View source ↗

Summary

Phase 4 study evaluating pegvisomant in combination with Sandostatin LAR for acromegaly has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sandostatin LAR (octreotide)
  • Somavert (pegvisomant)

Snippet

Sponsor: Pfizer | Conditions: Acromegaly | Phase 4 | Status: COMPLETED